Quantcast

Latest Trovagene Inc. Stories

2014-05-28 16:27:15

SAN DIEGO, May 28, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Financial Officer Stephen Zaniboni is scheduled to present a corporate overview at the Jefferies 2014 Global Healthcare Conference. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO Trovagene is scheduled to present at the Jefferies 2014 Global Healthcare Conference at the Grand Hyatt in New York, NY on Monday , June 2, 2014 at...

2014-05-28 08:27:55

Non-invasive detection and monitoring of actionable oncogene mutation in Erdheim-Chester disease serves as a model case for clinical utility SAN DIEGO, May 28, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that the multi-disciplinary clinical consensus guidelines for Erdheim-Chester disease (ECD), recently published online in the journal Blood, reference the ability of the Company's precision cancer monitoring...

2014-05-20 08:29:42

Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection SAN DIEGO, May 20, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that data published from ongoing clinical validation studies demonstrate that the company's precision cancer monitoring technology is suitable to non-invasively determine oncogene mutation status in patients with...

2014-05-14 16:29:04

SAN DIEGO, May 14, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). An additional abstract, submitted by Filip Janku, M.D., Ph.D., of The...

2014-05-12 16:28:41

SAN DIEGO, May 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2014. http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO "Our focus is to demonstrate the benefit of our precision cancer monitoring platform through research collaborations and expansion of our product offerings," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "In the first...

2014-05-05 16:27:05

SAN DIEGO, May 5, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that it will report financial results for the quarter ended March 31, 2014 on Monday, May 12, 2014 at 4:00 p.m. Eastern Daylight Time (1:00 p.m. Pacific Daylight Time). http://photos.prnewswire.com/prnvar/20120620/LA28014LOGO Trovagene's management team will host a conference call on Monday, May 12, 2014 at 5:00 p.m. Eastern Daylight Time (2:00 p.m....

2014-04-08 12:31:41

Study results show correlation between mutational status and treatment response, as well as concordance between BRAF V600E mutation assay and tissue biopsy at baseline SAN DIEGO, April 8, 2014 /PRNewswire/ -- Clinical study results presented today at the American Association for Cancer Research (AACR) Annual Meeting demonstrate the ability of Trovagene's (NASDAQ: TROV) molecular diagnostic platform to detect and monitor BRAF V600E mutations in cancer patients. The results were...

2014-04-01 08:28:44

SAN DIEGO, April 1, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that clinical data from a study using the company's cancer monitoring platform for the detection and longitudinal monitoring of BRAF V600E mutations will be the subject of a late-breaking poster presentation at the American Association for Cancer Research Annual Meeting in San Diego, California....

2014-03-26 08:29:02

SAN DIEGO, March 26, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that Charles Cantor, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Cantor, one of the leaders of the Human Genome Project, has published more than 400 peer reviewed articles, authored and co-authored more than 50 U.S. and international patents, and is also an author of the first genomics textbook, Genomics: The Science and...

2014-03-19 08:28:52

Partnership Seeks To Establish Clinical and Health Economic Benefits of Trovagene's Urine-Based Cell-Free Molecular Diagnostics for Potential Adoption in Cancer Management Strategies SAN DIEGO and BALTIMORE, March 19, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV) and Catholic Health Initiatives Center for Translational Research (CTR) today announced they have entered into a strategic partnership to conduct clinical validation studies, clinical utility studies, health economic...


Word of the Day
pungle
  • To take pains; labor assiduously with little progress.
This word comes from the Spanish 'pongale,' put it.
Related